The DOI matches its Crossref record.
Microangiopathy of the brain and retina
Abstract
Introduction There is paucity of data on safety, efficacy and outcomes of modified ATT regimens in patients with CLD. Aims and Objectives To study the efficacy and safety of treatment regimens for compensated (Group 1) and decompensated (group 2) liver disease group. Methods This was a randomized open labelled pilot study. Patients were given 6 months of ATT randomized to Isoniazid + Rifampicin + pyrazinamide + Ethambutol (HRZE) or Isoniazid + Rifampicin + Levofloxacin + Ethambutol (HRLE) in group 1 and 9 months of ATT randomized to Isoniazid + Levofloxacin + Ethambutol (HLE) or Rifampicin + Levofloxacin + Ethambutol (RLE) in group 2 respectively. Successful completion of ATT, development of hepatotoxicity, therapeutic response and overall survival was monitored. Results A total of 129 patients -60 in Group1 and 69 in Group 2 were included. Around 80 and 75 percent of patients in group 1 and 2 respectively were successfully treated with these regimens. The 6 month survival and incidence of hepatotoxicity was 98% vs 81% and 12.7% vs 13% in group 1 and 2 respectively (p-0.347). Mean therapeutic response was seen in 80 days vs 112 days (p-0.023) in group 1 and 2 respectively. High baseline AST and development of hepatotoxicity in HLE arm were found to be inversely correlated with survival (p < 0.05). Conclusions Treatment of TB in CLD is difficult and challenging, nevertheless success can be achieved with carefully planned treatment regimens and close monitoring. Low dose pyrazinamide can be used safely in compensated CLD; although the findings needs to be substantiated in further well controlled studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Vasospasm, its Role in the Pathogenesis of Diseases with Particular Reference to the Eye
Flammer, J., Pache, M., & Resink, T. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(00)00028-8 · Cited by 382
Characteristics of Susac syndrome: a review of all reported cases
Dörr, J., Krautwald, S., Wildemann, B., Jarius, S., Ringelstein, M., Duning, T., Aktas, O., Ringelstein, E. B., Paul, F., & Kleffner, I. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.82 · Cited by 365
MRI findings in Susac’s syndrome
Susac, J. O., Murtagh, F. R., Egan, R. A., Berger, J. R., Bakshi, R., Lincoff, N., Gean, A. D., Galetta, S. L., Fox, R. J., Costello, F. E., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000103880.29693.48 · Cited by 322
Self-citationThe primary vascular dysregulation syndrome: implications for eye diseases
Flammer, J., Konieczka, K., & Flammer, A. J. (2013) · EPMA Journal · doi:10.1186/1878-5085-4-14 · Cited by 313
Garg, N., Reddel, S. W., Miller, D. H., Chataway, J., Riminton, D. S., Barnett, Y., Masters, L., Barnett, M. H., & Hardy, T. A. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309649 · Cited by 76
Metadata
- Authors
- Susac, J. O., Hardman, J. M., & Selhorst, J. B.
- Venue
- Neurology
- Published
- 1979-03
- Volume
- 29
- Issue
- 3
- Pages
- 313-313
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2152779574
- Cited by
- 387
- References
- 0
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microangiopathy of the brain and retina. https://app.cochat.ai/papers/10.1212/wnl.29.3.313
- The paper
- Susac, J. O., Hardman, J. M., & Selhorst, J. B. (1979). Microangiopathy of the brain and retina. Neurology. https://doi.org/10.1212/wnl.29.3.313
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.